(+) Loxo Oncology ( LOXO ), which was surging by more than 65% after Eli Lilly ( LLY ) said it agreed to acquire the company for approximately $8 billion in cash to widen the breadth of its cancer treatments portfolio. Eli Lilly was down more than 2%.
(+) MYnd Analytics ( MYND ) was gaining more than 90% in value after saying it will merge with Emmaus Life Sciences Inc. in a stock-swap deal. Emmaus will become a wholly owned subsidiary of MYnd Analytics.
(+) Axsome Therapeutics ( AXSM ) was jumping by more than 190% as it reported that the second phase of a clinical trial of its AXS-05 oral treatment for major depressive disorder met its primary endpoint.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
Zeen is a next generation WordPress theme. It’s powerful, beautifully designed and comes with everything you need to engage your visitors and increase conversions.
Go to Appearance > Customize > Subscribe Pop-up to set this up.
Wealth Empire Newsletter
Register now for free updates and alerts
Note: I have the ability to revoke this permission at any time and ask for the removal of my personal data collected by contacting us or simply clicking Unsubscribe.